ATNX - Athenex inks licensing deal for Klisyri and Tirbanibulin

Athenex (ATNX) launches Klisyri (tirbanibulin) in the U.S., led by its partner Almirall. FDA approved Klisyri for the topical treatment of actinic keratosis of the face or scalp on December 14, 2020.Under the terms of the license agreement with Almirall, Athenex will receive up to $65M and more in milestone payments and tiered royalties starting at 15% based on annual net sales.Athenex also announced the licensing of additional territories for tirbanibulin to its partner PharmaEssentia.PharmaEssentia adds licensing rights to tirbanibulin for Japan and South Korea to already licensed territories, which include Taiwan, Singapore, and Malaysia.Under the expanded agreement, Athenex will receive an upfront payment, milestone payments and tiered double-digit royalties on net sales of tirbanibulin in Japan and South Korea.Shares up 2% premarket.

For further details see:

Athenex inks licensing deal for Klisyri and Tirbanibulin